The effect of HESA-A (natural drug) on visual acuity in age related macular degeneration: A randomized double blind controlled clinical trial

African Journal of Traditional, Complementary and Alternative Medicines

Volumn 6, Issue 4, 2009, Pages 549-553

  Ahmadi, Amrollah ^a   Ghanbari, Heshmatollah ^b   Soheilian, Masoud ^c   Naseri, Mohsen ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHED UNIVERSITY   (Iran)

Author keywords

Age related macular degeneration; HESA A

Indexed keywords

HESA A; NATURAL PRODUCT; PLACEBO; UNCLASSIFIED DRUG; HESA-A PREPARATION; PLANT MEDICINAL PRODUCT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; AGED; FLUORESCENCE ANGIOGRAPHY; MACULAR DEGENERATION; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PLANT PREPARATIONS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 70349446258     PISSN: 01896016     EISSN: 01896016     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ahmadi, A., Hajhashemi, V. and Balali, M. (2001a). Toxicological Studies on an Anticancer Drug (HESA-A) with Marine origin. Med. J. Islam. Acad. Sci., 14: 145-149.
2. Ahmadi, A., Mohgheghi, M.A. and Sharif-Tabrizi, A. (2001b). Introducing the therapeutic effects of HESA-A on osteosarcoma included in rabbits. Proceedings of the First National Congress on Cancer Research, Orumiah, Iran 5-8
3. Ahmadi, A., Naderi, G. and Asgary, S. (2005). Evaluation of hepatoprotective potential of HESA-A (a marine compound) pretreatment against thioacetamide-induced hepatic damage in rabbits. Drugs. Exp. Clin. Res., 31:1-6.
4. Ahmadi, A. and Sadeghi-Aliabadi, H. (2003). Cytotoxicity and Antitumor Properties of A Marine Compound, HESA-A, on Cancer cells. Daru., 11N: 3.
5. Blumenkranz, M.S., Bressler, N.M., Bressler, S.B., Donati, G., Fish, G.E., Haynes, L.A., et al. (2002). Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report no. 5. Arch. Ophthalmol., 120:1307-1314.
6. Ferris, F.L. III., Fine, S.L. and Hyman, L. (1984). Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol., 102: 1640-1642.
7. Gillies, M.C., Simpson, J.M., Luo, W., et al. (2003). A randomized clinical trial for a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. Arch. Ophthalmol., 121:667-673.
8. Giuliari, G.P. and Ciardella, A.P. (2007). The new face of age-related macular degeneration. Can. J. Ophthalmol. 42: 629-630
9. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T., et al (2004). Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med., 351:2805-2816.
10. Imrie, F.R. and Bailey, C. (2007). New treatments for age-related macular degeneration. Age. Ageing., 36: 8-10
11. Klein, R., Klein, B.E. and Linton, K.L. (1992). Prevalence of age related maculopathy: The beaver dam eye study. Ophthalmology., 99:933-943.
12. Korotkin, A., Kozak, I., Morrison, V.L., Magana, L., and Freeman, W.R. (2006). An emerging problem; recurrence of CNV in AMD is common after cessation of 24 month treatment with ranibizumab. Invest. Ophthalmol. Vis. Sci., 47:E-Abstract 2961.
13. Kyo, T., Yuzawa, M., Tochigi, K., Yamaguchi, T., Shimozuma, K., Fukuhara, S., Matsumoto, Y. (2007). Assessment of the quality of life in patients with age-related macular degeneration 1 year after photodynamic therapy. Nippon. Ganka. Gakkai. Zasshi., 111:315-321
14. Mitchell, P., Smith, W., Altebo, K. and Wang, J.J. (1995). Prevalence of age related maculopathy in Australia: The blue mountain eye study. Ophthalmology., 102:1450-1460.
15. Nirmalan, P.K., Katz, J., Robin, A.L., Tielsch, J.M., Namperumalsamy, P., Kim, R., et al (2004). Prevalence of vitreo-retinal disorders in a rural population of south India. The Arvind Comprehensive eye study. Arch. Ophthalmol., 122:581-586
16. Ruiz-Moreno, J.M., Montero, J.A., Barile, S. and Zarbin, M.A. (2006). Photodynamic therapy and highdose Intravitreal triamcinolone To treat exudative age-related Macular degeneration:1-year outcome. Retina., 26: 602-612
17. Sadeghi Aliabadi, H. and Ahmadi, A. (2001). Cytotoxicity and antitumor properties of a marine compound on cancer cells (HESA-A). Medical Journal of the Islamic Academy of Sciences. 13: 55-61
18. Schmidt-Erfurth, U.M. and Pruente, C. (2007). Management of neovascular age-related macular degeneration. Prog. Retin. Eye. Res., 26:437-451
19. Spaide, R. (2006). New treatments for AMD. Ophthalmology., 113:160-161.
20. Vingerling, J.R., Diclemans, I.J., Hofman, A., Grobbee, D.E., Hijmering, M., Kramer, F., et al. (1995). The prevalence of age related maculopathy in Rotterdam study. Ophthalmology., 102:205-210